Abstract: A food supplement formulation comprises quercetin, bromelain, papain, passiflora incarnata, valeriana officinalis, gotu kola, usnea barbata, althea officinalis, and L-arginine.

Abstract: The present invention refers to a new composition of a carrier substance for products to be aggregated comprising in its formulation more than 0.01% of papayne.

Abstract: Methods compositions and combinations for treating various diseases and conditions that are induced by cytokine activation and response, such as sepsis are provided. The method comprises orally administering a therapeutically effective amount of protease to a mammal to increase the inactivation of cytokines, such as TNF-alpha and INF-gamma. The composition comprises any pharmaceutically acceptable protease, for example, plant and microbial proteases may be used. The composition may be given, for example, singly or in combination with vitamins, minerals, antioxidants, bioflavonoids proanthocyanidins, herbs, herbal extracts, plant and animal concentrates, and non-prescriptive analgesics.

Abstract: The present invention relates to a method for the prevention or treatment of a disease mediated by decreased MMP-2 function. This may result from an aberrant interaction of molecules that stimulate or inhibit MMP-2 protein synthesis, stability, or function, as well as from mutations in the coding or regulatory regions of the gene encoding MMP-2. The invention also provides a method for identifying a substance useful in this context. It further contemplates a method for diagnosing such a disease.

Abstract: This invention relates to an enzymatic anhydrous hydrophilic wound debrider that uses in combination a proteolytic enzyme and an anhydrous hydrophilic poloxamer carrier.

Abstract: The invention relates to cathepsin O2 proteins, nucleic acids, and antibodies.

Abstract: the present invention application refers to a new pharmaceutical composition comprising carriers for products to be aggregated to the base of vitamin-E, papain and hyaluronidase, in the following quantities: 1 PAPAIN- 0.

Abstract: Disclosed are human interleukin-1 &bgr; converting enzyme like apoptosis proteases-3 and 4 and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Also provided are methods of using the polypeptides, for example, as an antitumor agent, and antiviral agent, and antibodies and antagonists against such polypeptides for example, for treating Alzheimer's disease, Parkinson's disease, rheumatoid arthritis and head injury.

Abstract: The present invention relates to a treating method for hair growth inhibition, which comprises administering (A) the extract of a plant of the family Juniperus or a malt. In addition, the present invention relates to a dermatologic composition for external use, which comprises (B) an elastase inhibitor or neutral endopeptidase inhibitor, and the above-described component (A) and/or (C) at least one proteolytic enzyme selected from the group consisting of papain, trypsin, chymotrypsin, pepsin, bromelain, ficin and pancreatin.

Abstract: Compositions and methods for treating corneal diseases mediated by elevated protease activity include ocular administration of protease inhibitors. One or more protease inhibitors selected from an aspartic, serine, cysteine, or metallo-protease inhibitor are administered to an ocular fluid, surface, or tissue, preferably by topical administration, to inhibit proteolytic activity associated with a corneal disease or condition, for example keratoconus. Antiproteolytic formulations of the invention may include carriers that prolong the retention and/or enhance delivery of the protease inhibitor. These formulations can also include other therapeutic agents such as antiinflammatory or antibiotic drugs. In preferred aspects of the invention, antiproteolytic formulations are administered during periods of closed eye tear production. Also provided within the invention are implant devices for corneal delivery of a protease inhibitor.

Abstract: The invention relates to a component of bromelain which is largely responsible for the ability of bromelain to interrupt the MAP kinase cascade. The component contains ananain and comosain and is useful in the treatment or prevention of diseases and conditions mediated by T cell activation or by activation of the MAP kinase pathway.

Abstract: An herbal formulation comprises betaine HCl, plant enzymes, papain, probiotic micro flora, fruitooligosaccharides, l-glutamine, quercitin, butyric acid, borage seed, flax seed, lecithin, gamma oryzanol, bromelain, pepsin, and N-acetylglucosamine.

Abstract: The present invention provides for filariid nematode cysteine protease proteins; to filariid nematode cysteine protease nucleic acid molecules, in particular, Dirofilaria immitis L3 larval cysteine protease nucleic acid molecules and Onchocerca volvulus L3 larval cysteine protease nucleic acid molecules; to antibodies raised against such proteins, and to compounds that inhibit filariid nematode cysteine protease activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies and/or inhibitors. The present invention also includes therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitors, and the use of such compositions to protect an animal from disease caused by parasitic helminths.

Abstract: Modified enzymes are prepared for use in skin care products by covalently coupling to the enzymes from 4 to 70 polymeric molecules with or without a linker such as a triazine ring. Molecular weight of the polymeric molecules may be from 1 to 35 kDa and of the enzymes from 15 to 100 kDa. The number and weight of polymeric molecules coupled is balanced with the weight and/or surface area of the enzymes. Enzymes include proteases such as subtilisins, lipases and oxidoreductases such as laccases and superoxide dismutase, and polymeric molecules include polysaccharides such as dextran or pullulan and polyalkylene oxides such as polyethylene glycol. The polymeric molecules may be coupled to the enzymes at the N-terminal amino group and/or lysine residues, and preferably at a position more than 5 Å from the active site of the enzymes. A preferred modified enzyme is a protease having from 5 to 13 coupled polymeric molecules.

Abstract: A method for treating various diseases and conditions that are dependent on activated &agr;2 macroglobulin in the blood and extravascular tissue is disclosed. The method comprises orally administering a therapeutically effective amount of protease to a mammal to increase the amount of activated &agr;2 macroglobulin, which in turn enhances the clearance of TNF-&agr;, leptin, and &bgr;-amyloid while enhancing delivery of TGF-&bgr;. The protease may be any pharmaceutically acceptable protease, and preferably is of microbial and/or plant origin, given singly or in combination with vitamins, minerals, antioxidants, bioflavonoids, proanthocyanidins, herbs, herbal extracts, plant and animal concentrates, and non-prescription analgesics. The microbial protease is preferably administered in a total daily dosage of at least 100,000 HUT (or equivalent biological activity). The plant protease component is preferably administered in a total daily dosage of at least 50,000 PU (or equivalent biological activity).

Abstract: A thermally stable enzyme composition contains an enzyme, and a heat stabilizer including a phospholipid and an oil-soluble vitamin. The enzyme composition can be prepared in the form of a powder by drying an enzyme solution containing a phospholipid and an oil-soluble vitamin to obtain an enzyme powder.

Abstract: The present invention relates to a treating method for hair growth inhibition, which comprises administering (A) the extract of a plant of the family Juniperus or a malt. In addition, the present invention relates to a dermatologic composition for external use, which comprises (B) an elastase inhibitor or neutral endopeptidase inhibitor, and the above-described component (A) and/or (C) at least one proteolytic enzyme selected from the group consisting of papain, trypsin, chymotrypsin, pepsin, bromelain, ficin and pancreatin.

Abstract: A composition for use in treating autism spectrum disorders. The composition preferably includes a genomeceutical type compound that increases the user's expression of DPPIV or like substances. The genomeceutical compound may include a sugar (such as a milk sugar), glucans, galactose and/or related material. The composition may also include one or more of a protease, peptidase or phytase. The inclusion of phospholipids, disaccharides, lipases and/or related substances in a composition for treating autism spectrum disorders and the function they provide is also disclosed.

Abstract: A procedure is described for obtaining valuable endoproteases (or zonases) from hatchery-produced Atlantic salmon eggs. Synchronized hatching by for instance elevated temperature, is followed by filtration through cheese cloth. The filtrate (hatching fluid) may be stored for months or year (depending on conditions) without loss of activity. Extraneous matters are removed by centrifugation (16,000 g, 2×15 min) after addition of urea (2 or 4 M, or more). High purity zonases are obtained by simple chromatographic procedures (gel filtration, affinity chromatography, isoelectric focusing), yielding sequence-grade purity after all three steps are performed in sequence. All preparations of salmon zonases exhibit valuable enzymatic properties with regard to proteolysis, both in terms of catalysis and stability.

Abstract: The present invention relates to the use of proteolytic enzymes for the prophylaxis and/or therapy of type I diabetes mellitus. The proteolytic enzymes are preferably used at the prediabetic stage.

Abstract: Isolated, substantially pure natural or synthetic polypeptides comprising cathepsin L type cysteine proteases, or polypeptide fragments or polypeptide admixtures obtained via proteolysis thereof, are useful for reducing intercorneocyte cohesion and, thus, for promoting desquamation.

Abstract: Compositions and methods to disinfect contact lenses are disclosed. In one embodiment, the present composition comprises a cellulose decomposing enzyme component, e.g., lysozyme, and a hydrogen peroxide destroying component. The composition is structured so that the cellulose decomposing enzyme component is released in a liquid medium containing hydrogen peroxide before the hydrogen peroxide destroying component is released in the liquid medium. Such cellulose decomposing enzyme component is preferably effective to render hydrogen peroxide-resistant microorganisms, e.g., acanthamoeba cysts, which may contaminate the lens more susceptible to being killed by hydrogen peroxide.

Abstract: A composition and a method for treatment of urinary tract dysfunction and, particularly, non-bacterial cystitis and, even more particularly, non-bacterial chronic interstitial cystitis. The composition primarily relies upon the use of a bioflavonoid and, particularly, that bioflavonoid known as quercetin. The quercetin is mixed with a proteolytic digestive enzyme protease, such as bromelin and papain, as the primary active ingredients. However, the composition may optionally and beneficially include other cystitis affecting agents, such as cranberry, as well as some other active and non-active ingredients.

Abstract: A composition and a method for treatment of prostate related dysfunction and, particularly, non-bacterial prostatitis and, even more particularly, non-bacterial chronic prostatitis. The composition primarily relies upon the use of a bioflavonoid and, particularly, that bioflavonoid known as quercetin. The quercetin is mixed with a proteolytic digestive enzyme protease, such as bromelin and papain, as the primary active ingredients. However, the composition may optionally and beneficially include other prostatitis affecting agents, such as zinc derived from zinc gluconate, cranberry, saw palmetto, as well as some other active and non-active ingredients.

Abstract: Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such ICE LAP-6 for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.

Abstract: The use of at least one hydrolytic enzyme and at least one flavonoid shows better activity than &agr;-interferon or ribavirin in the treatment of diseases caused by hepatitis C viruses.

Abstract: A method and apparatus enable the immune system of an infant to distinguish between ABBOS protein sections and p69 protein sections and reduces the risk that an infant will develop diabetes. The method cleaves protein-to-protein bonds in bovine serum albumin to reduce the similarity between the bovine serum albumin and pancreatic beta cells to minimize the likelihood that an infant will develop bovine serum albumin antibodies which will attack and kill the pancreatic beta cells.

Abstract: The present invention relates to parasite astacin metalloendopeptidase proteins, nucleic acid molecules having sequences that encode such proteins, antibodies raised against such proteins and compounds that can inhibit the activities of parasite astacin metalloendopeptidases. The present invention also includes methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitors. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites, such as heartworm infection.

Abstract: This invention relates to modulation of programmed cell death. It also relates to transgenic non-human animals comprising a disrupted Ich-3 gene and methods of making these animals. The Ich-3 mutant animals exhibit resistance to septic shock and defects in follficulogenesis. This invention also relates to methods of using the transgenic animals to screen for compounds to treat septic shock and defective folliculogenesis. Moreover, this invention also relates to methods of treating septic shock in normal individuals by inhibiting ICH-3.

Abstract: Soy hydrolysate compositions are produced by a process utilizing multiple enzymes. The soy hydrolysate compositions provide insect attractant and repellent properties. Methods of using the soy hydrolysate compositions for insect control are also disclosed.